Instinct Bio Swings to Profit, Revenue Up 9.8% in Yen on First Post-Listing Results
BIOT is trading near its 52-week low of $0.273 (2.4% above the low).
Summary
Instinct Bio reported its first financials since the July Nasdaq listing: 1H FY2026 revenue of USD 1.14M, up 4.7% in dollars and 9.8% in yen, with profit after tax of USD 90,251 versus a USD 206,817 loss a year earlier. The swing to profit came mostly from a 30.1% cut in administrative expenses as roughly USD 208,000 of non-recurring listing fees did not repeat, not from operating leverage. Gross margin fell to 72.6% from 79.7% on a smaller inventory build, new imported purchases and higher manufacturing overhead, and the company ended the period with just USD 25,565 of cash and no bank borrowings, relying on related-party support and receivables collection. Customer concentration improved, with the largest customer dropping to 34.8% of revenue from 51.7%. This lands against a September 15 disclosure of three Nasdaq delisting notices for minimum bid price, market value of listed securities and other deficiencies, so the profit headline does little to resolve the listing overhang. Management targets its Indonesia, INVITRX and IN01 initiatives operational by end of calendar 2026 with revenue contribution in fiscal 2027.
At the time of this announcement, BIOT was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $0.27 to $50.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.